Cargando…

IL-10 Induced by mTNF Crosslinking-Mediated Reverse Signaling in a Whole Blood Assay Is Predictive of Response to TNFi Therapy in Rheumatoid Arthritis

(1) Background: To date, the response of patients with rheumatoid arthritis (RA) to the various biologic DMARD available cannot be predicted due to a lack of reliable biomarkers. Based on our preliminary work on tmTNF reverse signaling, we developed a whole-blood assay measuring tmTNF crosslinking-i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krasselt, Marco, Gruz, Natalya, Pierer, Matthias, Baerwald, Christoph, Wagner, Ulf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225532/ https://www.ncbi.nlm.nih.gov/pubmed/35743787 http://dx.doi.org/10.3390/jpm12061003

Ejemplares similares

In vitro response pattern of monocytes after tmTNF reverse signaling predicts response to anti-TNF therapy in rheumatoid arthritis
por: Meusch, Undine, et al.
Publicado: (2015)

Metabolomics investigation of recombinant mTNFα production in Streptomyces lividans
por: Muhamadali, Howbeer, et al.
Publicado: (2015)

CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence
por: Krasselt, Marco, et al.
Publicado: (2013)

MtNF-YC6 and MtNF-YC11 are involved in regulating the transcriptional program of arbuscular mycorrhizal symbiosis
por: Deng, Chen, et al.
Publicado: (2022)

Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine
por: Mortara, Lorenzo, et al.
Publicado: (2013)

Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis
por: Krasselt, Marco, et al.
Publicado: (2016)

Deficient spontaneous in vitro apoptosis and increased tmTNF reverse signaling-induced apoptosis of monocytes predict suboptimal therapeutic response of rheumatoid arthritis to TNF inhibition
por: Meusch, Undine, et al.
Publicado: (2013)

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
por: Manders, Sofie HM, et al.
Publicado: (2015)

Mortality of Sepsis in Patients With Rheumatoid Arthritis: A Single-Center Retrospective Analysis and Comparison With a Control Group
por: Krasselt, Marco, et al.
Publicado: (2020)

Humoral Immunity to Varicella Zoster Virus in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis Compared to Healthy Controls
por: Krasselt, Marco, et al.
Publicado: (2021)

Negative association of the chemokine receptor CCR5 d32 polymorphism with systemic inflammatory response, extra-articular symptoms and joint erosion in rheumatoid arthritis
por: Rossol, Manuela, et al.
Publicado: (2009)

Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients
por: Pierer, Matthias, et al.
Publicado: (2006)

TNFi Cycling Versus Changing Mechanism of Action in TNFi‐Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2018)

Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics
por: Frisell, Thomas, et al.
Publicado: (2018)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis
por: Chen, Jing-Wen, et al.
Publicado: (2022)

COVID-19 Vaccination Coverage in Patients with Rheumatic Diseases in a German Outpatient Clinic: An Observational Study
por: Krasselt, Marco, et al.
Publicado: (2022)

Latent Cytomegalovirus Infection in Rheumatoid Arthritis and Increased Frequencies of Cytolytic LIR‐1+CD8+ T Cells
por: Rothe, Kathrin, et al.
Publicado: (2016)

Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis
por: Grabner, Michael, et al.
Publicado: (2017)

Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis
por: Cohen, Stanley, et al.
Publicado: (2022)

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
por: Mease, Philip J, et al.
Publicado: (2019)

Sepsis Mortality Is high in Patients With Connective Tissue Diseases Admitted to the Intensive Care Unit (ICU)
por: Krasselt, Marco, et al.
Publicado: (2021)

Outcome of Patients With Necrotizing Vasculitis Admitted to the Intensive Care Unit (ICU) for Sepsis: Results of a Single-Centre Retrospective Analysis
por: Krasselt, Marco, et al.
Publicado: (2020)

Brief Report: Deficient Thymic Output in Rheumatoid Arthritis Despite Abundance of Prethymic Progenitors
por: Wagner, Ulf, et al.
Publicado: (2013)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

Correction: Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
Publicado: (2017)

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
por: Druce, Katie L, et al.
Publicado: (2017)

Influenza, Pneumococcal and Herpes Zoster Vaccination Rates in Patients with Autoimmune Inflammatory Rheumatic Diseases
por: Krasselt, Marco, et al.
Publicado: (2023)

B lymphocytopenia in rheumatoid arthritis is associated with the DRB1 shared epitope and increased acute phase response
por: Wagner, Ulf, et al.
Publicado: (2002)

Peripheral CD4CD8 Double Positive T Cells with a Distinct Helper Cytokine Profile Are Increased in Rheumatoid Arthritis
por: Quandt, Dagmar, et al.
Publicado: (2014)

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD
por: Regierer, Anne Constanze, et al.
Publicado: (2021)

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices
por: Bansback, Nick, et al.
Publicado: (2020)

TNF-α, TNF-β, IL-6, and IL-10 Polymorphisms in Patients with Lung Cancer
por: Seifart, Carola, et al.
Publicado: (2005)

MtNF-YA1, A Central Transcriptional Regulator of Symbiotic Nodule Development, Is Also a Determinant of Medicago truncatula Susceptibility toward a Root Pathogen
por: Rey, Thomas, et al.
Publicado: (2016)

A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study
por: Jiang, Xia, et al.
Publicado: (2016)

Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis
por: Huynh, D H, et al.
Publicado: (2017)

Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis
por: G.S. Saad, Carla, et al.
Publicado: (2023)

Potential applicability of cytokines as biomarkers of disease activity in rheumatoid arthritis: Enzyme-linked immunosorbent spot assay-based evaluation of TNF-α, IL-1β, IL-10 and IL-17A
por: Dissanayake, Keerthie, et al.
Publicado: (2021)

Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy
por: Ehrenstein, Michael R., et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_ehlo9pop8630drvhionsrskm3k